What is the process of predicting future events?

Review

Selecting methods for the prediction of future events in cost-effectiveness models: a decision-framework and example from the cardiovascular field

Richard Grieve et al. Health Policy. 2003 Jun.

Abstract

Evidence on the cost-effectiveness of healthcare interventions is increasingly required by decision-makers. Economic models can provide timely information on the long-term impact of new technologies. However, models have been criticised because of the implicit assumptions they make, in particular the methods used to extrapolate data are rarely documented. This paper presents a systematic process for choosing a method of predicting events in economic models. This process is illustrated using a model examining the cost-effectiveness of a new HMG-CoA reductase inhibitor (statin) for primary prevention of cardiovascular disease (CVD). The prediction of future CVD events is a central component of the model, and the choice of method for predicting events was an important issue in the model's development. A literature review identified 11 studies with the information required to predict CVD events. A set of criteria were developed to assess the different methods of risk estimation, covering issues like scientific validity and acceptability to decision-makers. Risk equations derived from the Framingham Heart Study were found to be most suitable for predicting future events in the economic model. The paper illustrates how the development of economic models can be made more transparent, and suggests that the process outlined may be applied to other disease areas where there are several event prediction methods to choose from. In disease areas where published methods for predicting events are not available, the process outlined can make the uncertainty this leads to explicit, and highlight where further research is required. Such transparency can help decision-makers understand the scientific basis underpinning models, and therefore make these models more acceptable and useful for health policy-making.

Similar articles

  • [Analysis of cost-effectiveness of simvastatin versus atorvastatin in the secondary prevention of cardiovascular events within the Brazilian public healthcare system].

    Araujo DV, Ribeiro de Souza CP, Bahia LR, Rey HC, Dos Santos Junior B, Tura BR, Berwanger O, Buehler AM, Silva MT. Araujo DV, et al. Value Health. 2011 Jul-Aug;14(5 Suppl 1):S29-32. doi: 10.1016/j.jval.2011.05.024. Value Health. 2011. PMID: 21839894 Portuguese.

  • Modeling the costs and long-term health benefits of screening the general population for risks of cardiovascular disease: a review of methods used in the literature.

    Epstein D, García-Mochón L, Kaptoge S, Thompson SG. Epstein D, et al. Eur J Health Econ. 2016 Nov;17(8):1041-1053. doi: 10.1007/s10198-015-0753-2. Epub 2015 Dec 18. Eur J Health Econ. 2016. PMID: 26682549 Free PMC article. Review.

  • Asymptomatic peripheral arterial disease: is pharmacological prevention of cardiovascular risk cost-effective?

    Sigvant B, Henriksson M, Lundin F, Wahlberg E. Sigvant B, et al. Eur J Cardiovasc Prev Rehabil. 2011 Apr;18(2):254-61. doi: 10.1177/1741826710389368. Epub 2011 Jan 28. Eur J Cardiovasc Prev Rehabil. 2011. PMID: 21450673

  • Cost-effectiveness of statins in the primary prevention of cardiovascular disease: a systematic review and economic analysis for Belgium.

    Neyt M, De Laet C, Van Brabandt H, Franco O, Ramaekers D. Neyt M, et al. Acta Cardiol. 2009 Feb;64(1):1-10. doi: 10.2143/AC.64.1.2034354. Acta Cardiol. 2009. PMID: 19317290 Review.

Cited by

  • Economic evaluation of a single-pill triple antihypertensive therapy with valsartan, amlodipine, and hydrochlorothiazide against its dual components.

    Stafylas P, Kourlaba G, Hatzikou M, Georgiopoulos D, Sarafidis P, Maniadakis N. Stafylas P, et al. Cost Eff Resour Alloc. 2015 Jun 9;13:10. doi: 10.1186/s12962-015-0036-x. eCollection 2015. Cost Eff Resour Alloc. 2015. PMID: 26097434 Free PMC article.

  • Statin therapy in rheumatoid arthritis: a cost-effectiveness and value-of-information analysis.

    Bansback N, Ara R, Ward S, Anis A, Choi HK. Bansback N, et al. Pharmacoeconomics. 2009;27(1):25-37. doi: 10.2165/00019053-200927010-00004. Pharmacoeconomics. 2009. PMID: 19178122

  • Development and validation of a model to project the long-term benefit and cost of alternative lipid-lowering strategies in patients with hypercholesterolaemia.

    Cook JR, Yin D, Alemao E, Drummond M. Cook JR, et al. Pharmacoeconomics. 2004;22 Suppl 3:37-48. doi: 10.2165/00019053-200422003-00005. Pharmacoeconomics. 2004. PMID: 15669152

Publication types

MeSH terms

Substances